Thi-inducing adjuvant comprising combination of different nucleic acid adjuvants and use of same
AssigneeKen ISHII
InventorsKen ISHII, Etsushi KURODA, Burcu Temizoz
Life of this patent
Estimating the term…
Loading patent…
AssigneeKen ISHII
InventorsKen ISHII, Etsushi KURODA, Burcu Temizoz
Estimating the term…
The present invention provides the induction of novel Th1 response, the induction of cytotoxic T cells and anti-cancer/anti-allergic activity techniques. Provided is a combination of a CpG oligonucleotide and an STING agonist. Also provided is a composition which contains an STING agonist, can be used as a type-I adjuvant, and is characterized in that the STING agonist is administered together with a CpG oligonucleotide. Further provided is an anti-cancer agent comprising a CpG oligonucleotide and is characterized in that the CpG oligonucleotide is administered together with an STING agonist. Still further provided is a composition which contains a CpG oligonucleotide and can be used for reducing or eliminating the IgE-inducing activity of an STING agonist.
A combination of a CpG oligonucleotide and a STING agonist.
-28. (canceled)
A method of treating or preventing a disease or condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a CpG oligonucleotide and a therapeutically effective amount of a stimulator of interferon genes (STING) agonist.
A method of at least one of:
Dependencies are inferred from the claim text.